Terry Pirovolakis

Terry Pirovolakis, co-founder of CureSPG50, confronted his child's SPG50 diagnosis in 2019. Through successful fundraising, he led ground-breaking research, treating three children within three years. Pirovolakis established Elpida Therapeutics, non-profit, focusing on gene therapies for ultra-rare conditions. Collaborating with industry leaders, Elpida targets SPG50, CLN7, CMT4J, Lafora, and plans to address two more diseases in 2026, utilizing profits to sustain programs. Pirovolakis extends his impact by supporting foundations, providing Gene Therapy 101 classes, and engaging in collaborations, all centered on the goal of saving as many children as possible.

Please note that speakers provide their own biographies and headshots. Biographies represent the role of the person at the time of their engagement and are not independently verified by the Milken Institute.